Chronic Disease ; prevention & control ; Humans ; Population Surveillance ; methods

OBJECTIVE: To explore the effect of tanshinone II A (Tan II A) on the myocardial apoptosis in rats with sepsis. METHODS: The sepsis rat model was established by cecal ligation and puncture operation (CLP), and the Tan II A was given for 12 consecutive hours. Then, the following indices were measured such as the activities of Na+-K+-ATPase and SOD, the contents of TNF-α, IL-1β, calcium, MDA, apoptotic index and the protein level of Bcl-2, Bax, Fas, caspase-3, calcincurin in myocardial. RESULTS: CD Compared with sham group, CLP treatment can result in decreased myocardial activities of Na+-K+-ATPase and SOD, elevated the contents of IL-1β, calcium, MDA (P<0.05); Tan II A treatment can improve the above aberrant indices. (2) Compared with sham group, CLP treatment can elevated the myocardial apoptotic index (P<0.05), and Tan II A treatment can decrease the elevation of apoptotic index by CLP treatment (P<0.05); (3)Compared with sham group, the protein level of Bax, Fas, caspase-3 and calcincurin significantly increased, and protein level of Bcl-2 decreased (P<0.05) in CLP group, and Tan II A treatment can improve exceptional expression of the above proteins (P<0.05). CONCLUSION: Tanshinone II A shows a protective effect on the myocardial apoptosis in septic rats maybe by depressing inflammatory infiltration and oxidative stress reaction, relieving calcium overload and partly improving the exceptional expression of the proteins such as Bax, Bcl-2, Fas, caspases-3 and calcincurin.

Objective To investigate the value of detecting BK virus(BKV)in urine of renal al- lograft recipients for the diagnosis and treatment of BKV infection.Methods Using polymerase chain re- action(PCR)method combined with DNA sequencing,61 urine samples from renal allograft recipients,30 u- fine samples from dialytic patients and 30 urine samples from healthy volunteers(controls)were detected. The results were compared among the 3 groups.Results The BKV positive rate in renal allograft recipi- ents was 36.1%,compared with 13.3% in dialytic patients(P＜0.05)and 0.0% in controls(P＜0.05). One renal allograft recipient who was positive for BKV developed ureteral obstruction.The BKV positive rate was 40.9%(9/22)in renal allograft recipients with rejection episode,compared with 33.3%(13/39)in the recipients without rejection episode(P＞0.05);and the BKV positive rate was 36.0%(18/50)in the recip- ients with normal graft function,compared with 36.4%(4/11)in the recipients with abnormal graft function (P＞0.05).Conclusions Renal allograft recipients are the high risk population who may develop BKV viruria.There is no correlation between recipients with or without rejection episode and BKV viruria,and also no correlation between recipients with normal or abnormal graft function and BKV viruria.Detection of BKV in the urine of renal allograft recipients is helpful in differential diagnosis of BKV induced ureteral obstruc- tion,and PCR method for detecting BKV DNA can be used to screen for BK virus-associated nephropathy (BKVAN).

Objective To explore the role and significance of standardized scheme for diagnosis and treatment of pulmonary thromboembolism(PTE).Methods The clinical data of 163 consecutive PTE patients who were treated in our hospital from Jan.1972 to Dec.2006 were retrospectively reviewed.The patients were divided into group A and group B based on the time of application of standardized treatment and diagnosis for PTE.The clinical data of the two groups were analyzed and compared.Results The main risk factors included deep vein thrombus,operation,injury,fracture and tumors,etc.Dyspnea was the most important clinical symptoms.The incidences of dyspnea in group A and B were 92.5% and 84.6%,respectively.The diagnostic case and the ratio of final diagnosis in group B was increased compared to those in group A on an annual basis.The median time for diagnosis was shortened(P

Asphyxia Neonatorum ; complications ; Biomarkers ; urine ; Dinoprost ; analogs & derivatives ; urine ; Disease Progression ; Female ; Humans ; Hypoxia-Ischemia, Brain ; diagnosis ; etiology ; urine ; Infant, Newborn ; Male ; Predictive Value of Tests ; Severity of Illness Index ; Time Factors

Objective To investigate the predictive value of combined analysis on single nucleotide polymorphisms (SNPs) of X-ray cross-complementing1 ( XRCC1 ) gene 194 and 399 codon,xeroderma pigmentosum group D (XPD) gene 312 codon and glutathione S-transferase P1 (GSTP1) gene 105 codon in platinum based chemotherapy.Methods Direct sequencing was performed to detect XRCC1,XPD and GSTP1 genotypes in peripheral blood from 50 cancer patients receiving platinum-based chemotherapy.Genetic polymorphisms of these genes related to sensitivity of platinum were reviewed.Results Favorable genotypes were Arg/Trp and Trp/Trp in XRCC1 194 codon,Arg/Arg in XRCC1 399 codon,Asn/Asn in XPD 312 codon and Val/Val in GSTP1 105 codon.The response rate to chemotherapy was 57.1％,75.0％,60.9％,85.7％ and 87.5％,respectively.The response rate for patients possessing ≥2 favorable genotypes and those possessing 1 or 0 favorable genotype was 78.9％,36.4％ and 0,respectively.Patients possessing ≥2 favorable genotypes demonstrated higher sensitivity to platinum based chemotherapy,compared with those possessing 1 or 0 favorable genotype ( x2 =25.79,P ＜ 0.01 ).Conclusions Combination analysis of genomic polymorphisms of XRCC1,XPD and GSTP1 may be useful in predicting sensitivity of platinum based chemotherapy.

Antimony ; blood ; Humans ; Spectrophotometry, Atomic ; methods

Objective To analyze the hospitalization expenses of cancer patients covered with byitem payment and quota payment packages,and probe into the impacts on such expenses for the two payment packages.Methods Inpatient records of 600 cancer patients were sampled by random from the medical insurance databases of Zhengzhou and Fuzhou to learn their hospitalization expenses and impact factors.Results Under the by-item payment package,the expenses of urban workers’ medical insurance were found higher than those of urban residents' medical insurance,with a per capita expense of RMB 32747.70 ± 32035.01 and 23035.83 ± 22875.65 respectively.Under the quota payment package however,there were no significant differences between expenses of the two kinds of inpatients,with a per capita expense of RMB 66043.41±47562.09 and 66576.54±73417.29 respectively.Conclusion There are gaps of reimbursement level between the two basic insurance schemes,which may not disappear in a short time.Under the by-item payment package,the gap exists in the difference of perreimbursement amount; under the quota payment package,the gap is negligible between the two populations under different insurance schemes.It is recommended to make reasonable use of these different payment schemes to minimize the relative gaps in medical service accessibility caused by the difference in reimbursement level.

0.05), the leukopenia rates 78.13%(25/32)vs 50.00%(17/34)(P

Traditional Chinese medicines (TCM) is one of the most important sources of new drugs.The rapid development of modern science and technology has brought new opportunities for TCM.Admittedly,new academic theory is getting into a golden period of innovation.Key technologies that enbody TCM features and adapt to modern drug-screening requirements are urgently needed.After five years' endeavor,the authors' group has made great progress in the new theories and methodologies for the discovery of bioactive compounds from TCM.In this review,a total of five key technologies:library-bioactivity-structure integration,biological and chemical fishing technology,ligand-and receptor-based virtual screening,profile-bioactivity relationship and the technology for discovering bioactive equivalent combinatorial components (BECCs),were introduced.In the text,several valuable demonstrations over the TCM-based drug discovery were provided,for uncovering the scientific basis of TCM and accelerating the process of TCM modernization.